Ionis Pharmaceuticals (IONS) Q4 2024 earnings summary

Executive summary

• Transitioned to a fully integrated commercial-stage biotech with the independent launch of TRYNGOLZA for FCS in December 2024, following FDA approval and marking a first-mover advantage.

• WAINUA launch for hereditary ATTR polyneuropathy delivered substantial sequential growth and positive patient experience.

• Donidalorsen for HAE and olezarsen for SHTG progressing toward regulatory milestones and launches, with donidalorsen launch expected in 2025.

• Rich late-stage pipeline with 9 medicines in Phase 3 for 11 indications, targeting multi-billion dollar opportunities and multiple late-stage partner program launches expected.

Financial highlights

• 2024 revenue reached $705M, exceeding guidance by over $130M, driven by commercial and R&D revenue.

• 2024 non-GAAP operating loss was $345M, a significant improvement over guidance; GAAP operating loss was $475M.

• Operating expenses for 2024 were $1.05B (non-GAAP) and $1.18B (GAAP), reflecting commercialization efforts.

• Cash, cash equivalents, and short-term investments totaled $2.3B at year-end 2024, exceeding revised guidance.

• Commercial revenue was $293M, with SPINRAZA royalties at $216M, WAINUA product sales at $85M, and WAINUA royalties at $20M.

Outlook and guidance

• 2025 revenue guidance set at over $600M, with non-GAAP operating loss expected to be less than $495M and year-end cash near $1.7B.

• Revenue growth to be powered by TRYNGOLZA sales, potential donidalorsen launch, growing WAINUA royalties, and significant SPINRAZA royalties.

• Continued investment in commercialization for TRYNGOLZA and donidalorsen, and in advancing pipeline including ION582 for Angelman syndrome.

• Multi-billion-dollar peak revenue potential from pipeline; positive cash flow targeted as revenue grows.